110140-89-1
110140-89-1
Chemical Structure
Ridogrel
Synonym(s): R 68070
- CAS. Nr.: 110140-89-1
- Formula:C18H17F3N2O3
- Molecular Weight:366.33
IUPAC Name: (E)-5-(((pyridin-3-yl(3-(trifluoromethyl)phenyl)methylene)amino)oxy)pentanoic acid
InChIKey: GLLPUTYLZIKEGF-HAVVHWLPSA-N
SMILES: O=C(O)CCCCO/N=C(C1=CC=CN=C1)\C2=CC=CC(C(F)(F)F)=C2
Biological Activity: Ridogrel (R 68070) is an orally active combined thromboxane A2 synthetase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor blocker. Ridogrel is potent antiplatelet agent. Anti-inflammatory activities[1][2][3].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Ridogrel | 99.28% | Ridogrel (R 68070) is an orally active combined thromboxane A2 synthetase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor blocker. Ridogrel is potent antiplatelet agent. Anti-inflammatory activities. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ridogrel (Standard) | ≥98% | Ridogrel (Standard) is the analytical standard of Ridogrel. This product is intended for research and analytical applications. Ridogrel (R 68070) is an orally active combined thromboxane A2 synthetase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor blocker. Ridogrel is potent antiplatelet agent. Anti-inflammatory activities. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. De Clerck F, et al. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--II. Pharmacological effects in vivo and ex vivo. Thromb Haemost. 1989;61(1):43-49. [Content Brief]
- [2]. Di Perri T, et al. Ridogrel, una nuova molecula antiaggregante piastrinica a doppio meccanismo d'azione. Profilo farmacologico e clinico [Ridogrel, a new platelet antiaggregant molecule with a double mechanism of action. A pharmacological and clinical profile]. Recenti Prog Med. 1991;82(10):533-540. [Content Brief]
- [3]. Carty E, et al. Ridogrel, a dual thromboxane synthase inhibitor and receptor antagonist: anti-inflammatory profile in inflammatory bowel disease. Aliment Pharmacol Ther. 2000;14(6):807-817. [Content Brief]
Keywords
